Pinnacle Associates Ltd. reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 44.4% in the ...

This transaction increased Vanguard's total holdings in Vertex to 6,721,315 shares, reflecting a significant endorsement of Vertex's market position and business model. The shares were purchased ...

We expect investors to focus on the launch plans of Arcturus Therapeutics Holdings Inc.’s ARCT self-amplifying mRNA (sa-mRNA) ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

Return on Assets (ROA): Zeta Global Holdings's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.95%, the company may face hurdles in ...

Adjacent angles are one of the earliest and most important concepts to learn in basic geometry, as they have applications in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...